A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)

Study category: Eyes

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Proptosis/Eye bulging

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Prem Subramanian,  MD, PhD

Prem Subramanian, MD, PhD

Study ID

Protocol Number: 21-4929

More information available at ClinicalTrials.gov: NCT05176639

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers